[go: up one dir, main page]

MX2019001999A - Proceso para la preparacion de microparticulas que contienen acetato de glatiramer. - Google Patents

Proceso para la preparacion de microparticulas que contienen acetato de glatiramer.

Info

Publication number
MX2019001999A
MX2019001999A MX2019001999A MX2019001999A MX2019001999A MX 2019001999 A MX2019001999 A MX 2019001999A MX 2019001999 A MX2019001999 A MX 2019001999A MX 2019001999 A MX2019001999 A MX 2019001999A MX 2019001999 A MX2019001999 A MX 2019001999A
Authority
MX
Mexico
Prior art keywords
glatiramer acetate
microparticles containing
preparing microparticles
containing glatiramer
preparing
Prior art date
Application number
MX2019001999A
Other languages
English (en)
Inventor
Marom Ehud
Rubnov Shai
Bleich Kimelman Nadav
Original Assignee
Mapi Pharma Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Mapi Pharma Ltd filed Critical Mapi Pharma Ltd
Publication of MX2019001999A publication Critical patent/MX2019001999A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5031—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poly(lactide-co-glycolide)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5094—Microcapsules containing magnetic carrier material, e.g. ferrite for drug targeting
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/001—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof by chemical synthesis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2/00—Peptides of undefined number of amino acids; Derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08G—MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
    • C08G69/00—Macromolecular compounds obtained by reactions forming a carboxylic amide link in the main chain of the macromolecule
    • C08G69/02—Polyamides derived from amino-carboxylic acids or from polyamines and polycarboxylic acids
    • C08G69/36—Polyamides derived from amino-carboxylic acids or from polyamines and polycarboxylic acids derived from amino acids, polyamines and polycarboxylic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Dermatology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Polymers & Plastics (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Epoxy Compounds (AREA)

Abstract

La presente invención proporciona un procedimiento mejorado para la preparación de micropartículas que contienen acetato de glatiramer con bajos niveles de disolventes orgánicos residuales, en particular, diclorometano. Las micropartículas se incorporan en composiciones farmacéuticas parenterales de acción prolongada en forma depot que son adecuadas para administración o inyección subcutánea o intramuscular, y que se pueden utilizar para el tratamiento de la esclerosis múltiple.
MX2019001999A 2016-08-28 2017-08-28 Proceso para la preparacion de microparticulas que contienen acetato de glatiramer. MX2019001999A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201662380426P 2016-08-28 2016-08-28
PCT/IL2017/050954 WO2018042423A1 (en) 2016-08-28 2017-08-28 Process for preparing microparticles containing glatiramer acetate

Publications (1)

Publication Number Publication Date
MX2019001999A true MX2019001999A (es) 2019-08-29

Family

ID=61301634

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2019001999A MX2019001999A (es) 2016-08-28 2017-08-28 Proceso para la preparacion de microparticulas que contienen acetato de glatiramer.

Country Status (10)

Country Link
US (1) US11471421B2 (es)
EP (1) EP3503907B1 (es)
JP (2) JP7232752B2 (es)
CN (1) CN109689082A (es)
AU (1) AU2017319781B2 (es)
BR (1) BR112019003131A2 (es)
ES (1) ES2979169T3 (es)
IL (1) IL264824B (es)
MX (1) MX2019001999A (es)
WO (1) WO2018042423A1 (es)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US12097292B2 (en) 2016-08-28 2024-09-24 Mapi Pharma Ltd. Process for preparing microparticles containing glatiramer acetate
DK3506921T3 (da) * 2016-08-31 2023-07-31 Mapi Pharma Ltd Depotsystemer, der omfatter glatirameracetat
JP7602322B2 (ja) * 2017-03-26 2024-12-18 マピ ファーマ リミテッド 進行型の多発性硬化症を治療するためのグラチラマーデポシステム
CN111249524B (zh) * 2020-01-18 2020-12-08 南京医科大学附属口腔医院 用于骨组织再生的高孔隙率聚己内酯多孔微球支架及其制备方法
WO2023170493A1 (en) * 2022-03-07 2023-09-14 Hadidi Naghmeh Drug delivery using a parenteral pharmaceutical composition

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5800808A (en) 1994-05-24 1998-09-01 Veda Research And Development Co., Ltd. Copolymer-1 improvements in compositions of copolymers
US5945126A (en) * 1997-02-13 1999-08-31 Oakwood Laboratories L.L.C. Continuous microsphere process
US8871241B2 (en) 2002-05-07 2014-10-28 Psivida Us, Inc. Injectable sustained release delivery devices
CN1398584A (zh) 2002-07-15 2003-02-26 裴福兴 一种bFGF－PLGA缓释微球及其制备方法和用途
JP2007500693A (ja) 2003-07-31 2007-01-18 イエダ リサーチ アンド デベロップメント カンパニー リミテッド 移植片拒絶反応を予防するための合成ペプチドコポリマーを含む併用療法
TR201818858T4 (tr) 2010-01-04 2019-01-21 Mapi Pharma Ltd Glati̇ramer asetat i̇çeren depo si̇stemi̇.
US8377885B2 (en) 2010-01-04 2013-02-19 Mapi Pharma Ltd. Depot systems comprising glatiramer or pharmacologically acceptable salt thereof
ES2601892T3 (es) 2011-04-21 2017-02-16 Mapi Pharma Limited Pentapolímero aleatorio para el tratamiento de enfermedades autoinmunes
CN103169670B (zh) * 2013-03-22 2016-07-06 深圳翰宇药业股份有限公司 一种醋酸格拉替雷微球及其制备方法
DK3506921T3 (da) 2016-08-31 2023-07-31 Mapi Pharma Ltd Depotsystemer, der omfatter glatirameracetat
JP7602322B2 (ja) 2017-03-26 2024-12-18 マピ ファーマ リミテッド 進行型の多発性硬化症を治療するためのグラチラマーデポシステム

Also Published As

Publication number Publication date
JP2019537551A (ja) 2019-12-26
CN109689082A (zh) 2019-04-26
AU2017319781B2 (en) 2021-05-27
AU2017319781A1 (en) 2019-02-07
ES2979169T3 (es) 2024-09-24
JP2023022199A (ja) 2023-02-14
EP3503907A1 (en) 2019-07-03
EP3503907C0 (en) 2024-03-13
IL264824B (en) 2022-03-01
BR112019003131A2 (pt) 2019-05-21
EP3503907B1 (en) 2024-03-13
JP7232752B2 (ja) 2023-03-03
CA3035149A1 (en) 2018-03-08
WO2018042423A1 (en) 2018-03-08
US11471421B2 (en) 2022-10-18
US20210299057A1 (en) 2021-09-30
EP3503907A4 (en) 2020-05-20

Similar Documents

Publication Publication Date Title
MX2019001999A (es) Proceso para la preparacion de microparticulas que contienen acetato de glatiramer.
HK1245080A1 (zh) 自然杀伤细胞的方法和组合物
EA201791560A1 (ru) Порошковый состав для интраназального введения для лечения гипогликемии
MY194058A (en) Cyclic dinucleotides for treating conditions associated with sting activity such as cancer
PL3418403T3 (pl) Hydrometalurgiczny proces obróbki do ekstrakcji pierwiastków szlachetnych, nieszlachetnych i rzadkich
WO2016109546A3 (en) Methods and compositions for prognosis and treatment of cancers
MX2019010404A (es) Compuestos sulfamida cíclicos y métodos de uso de los mismos.
MX2020007477A (es) Formulacion para la administracion de arn.
MX2018009325A (es) Compuestos y metodos para tratar enfermedades mediadas por el acido ribonucleico (arn).
MX2018011114A (es) Métodos y composiciones relacionadas con crispr/cas para el tratamiento de beta hemoglobinopatías.
MX2017001288A (es) Composicion para el tratamiento de telas que comprende una nanoemulsion de polimero de aminosiloxano.
MD20180042A2 (ro) Metode de tratare a stărilor asociate cu activarea complementului dependentă de MASP-2
CA2939791C (en) Needle assisted jet injection administration of testosterone compositions
MX2017006942A (es) Nuevos derivados de ester fosforamidato 3'-desoxiadenosina de 2' y/o 5' aminoacido como compuestos anti-cancer.
PH12016500320A1 (en) Cyclosporin analogues for preventing or treating hepatitis c
WO2018226992A8 (en) Tau aggregation inhibitors
NZ710602A (en) Methods for reducing pyrogenicity in a seaweed extract
JOP20200004A1 (ar) تركيبات طويلة المفعول
AU2017260426A1 (en) Engineered nucleases useful for treatment of hemophilia A
PH12017500098A1 (en) Suspension compositions of cyclosporin a for subconjunctival and periocular injection
MX2018011875A (es) Reprogramacion cardiaca directa mejorada.
MX391474B (es) Péptidos cíclicos derivados de cd44v6 para el tratamiento de enfermedades relacionadas con cánceres y angiogénesis
PH12019502578A1 (en) Methods of treatment for cervical dystonia
PH12020550795A1 (en) Methods of using and compositions containing dulaglutide
EP3925968A3 (en) Hsp70-derived peptide, pharmaceutical composition for treating or preventing cancer using same, immunity inducer, and method for producing antigen-presenting cell